Skip to content

Rolling Out Depot Buprenorphine – there is no Red Carpet

Wednesday, April 28th 2021
7:00 PM - 9:00 PM

It will soon be 2 years since the first depot buprenorphine product (Buvidal®) was made available in Australia via a product familiarisation programme, 18 months since it was TGA approved, and a year since another depot buprenorphine product (Sublocade®) was PBS listed, for treatment of opioid dependence. In this seminar we look at challenges in the delivery of this treatment modality in a range of metropolitan and regional settings as a case study for the larger question of how to make addiction treatment more available to the people who need it, whoever and wherever they are.

Health Professionals, stay up to date with the latest PHN news in your region
Subscribe to our newsletter